An Open-Label Phase 1 Study to Determine the Pharmacokinetics, Metabolism, and Routes of Excretion of (14C) Radiolabeled PCI-32765 in Healthy Male Subjects
Latest Information Update: 17 Sep 2015
At a glance
- Drugs Ibrutinib (Primary)
- Indications Allergic rhinitis; Haematological malignancies; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 01 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Aug 2012 New trial record